NanoString® Technologies has secured an option to an exclusive worldwide license for a 186-gene signature that could be used to determine the prognosis of patients diagnosed with the most common type of liver cancer, hepatocellular carcinoma (HCC). "This platform could provide the multiplexed gene expression capabilities needed for clinical diagnostic use of this HCC gene signature, especially given the potential for a large-scale global surveillance testing opportunity," said Yujin Hoshida, MD, PhD, who led the discovery of the signature while a postdoctoral fellow at Broad Institute and is on the faculty at Mount Sinai. "By identifying those HCC patients who are at the greatest risk of recurrence, doctors may choose to monitor these patients more regularly or to enter them into clinical trials in the adjuvant setting to reduce the risk of HCC recurrence," said Josep M. Llovet, MD, professor of medicine and director of the HCC Program at Mount Sinai. Learn more